What are the major opportunities in the Treatment Resistant Depression market? What are the strategies for the Treatment Resistant Depression market?

For detailed insights on the major opportunities and strategies in the Treatment Resistant Depression market, Read More

How does the Treatment Resistant Depression market relate to the overall economy and other similar markets?

For detailed insights on Treatment Resistant Depression's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Treatment Resistant Depression market growth? SWOT analysis of the Treatment Resistant Depression market.

For detailed insights on the key dynamics influencing the Treatment Resistant Depression market growth and SWOT analysis of the Treatment Resistant Depression industry, Read More

Global Treatment-Resistant Depression Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

Treatment-Resistant Depression Global Market Report 2025

Name: Treatment-Resistant Depression Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIS), Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Psychedelics, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Treatment-Resistant Depression Market Overview

• Treatment-Resistant Depression market size has reached to $1.76 billion in 2024

• Expected to grow to $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%

• Growth Driver: High Prevalence Of Mental Disorders Driving The Market Due To Increasing Incidence Of Treatment Non-Response

• Market Trend: Innovative Therapies To Address Unmet Patient Needs In Treatment-Resistant Depression

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Treatment-Resistant Depression Market?

Treatment-resistant depression (TRD) is a severe and persistent form of major depressive disorder (MDD) characterized by inadequate response to at least two different antidepressant treatments of adequate dose and duration, leading to prolonged psychological distress and functional impairment. Individuals with TRD often require advanced therapeutic approaches, including novel pharmacological treatments, neuromodulation techniques, and personalized mental health interventions, to achieve symptom relief and improve overall well-being.

The main drug classes in treatment-resistant depression are selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, tricyclic antidepressant, psychedelics, and others. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant medications that function by increasing serotonin levels in the brain by inhibiting its reabsorption into neurons, thereby enhancing mood regulation and treating conditions such as depression and anxiety disorders. The drugs are administered through routes including oral, parenteral, and others, which are distributed by various channels such as hospital pharmacies, retail pharmacies, and online pharmacies for the end users, including hospitals, homecare, specialty clinics, and others.

Treatment-Resistant Depression Market Size and growth rate 2025 to 2029: Graph

What Is The Treatment-Resistant Depression Market Size 2025 And Growth Rate?

What Is The Treatment-Resistant Depression Market Growth Forecast?

The treatment-resistant depression market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to an increase in chronic diseases, increasing prevalence of anxiety disorders, growing awareness of mental health, increase in government initiatives, and increase in healthcare expenditure. Major trends in the forecast period include telemedicine and digital health expansion, advancements in diagnostic and therapeutic technologies, mental health awareness and stigma reduction, adoption of personalized medicine, and use of artificial intelligence.

The forecast of 6.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. mental health progress by inflating prices of esketamine nasal sprays and deep TMS devices manufactured in Belgium and Israel, resulting in delayed intervention for severe depression and higher psychiatric care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Treatment-Resistant Depression Market Segmented?

1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS), Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Psychedelics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) Selective Serotonin Reuptake Inhibitors (SSRIs): fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram

2) Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

3) Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin

4) Psychedelics: Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), Other Drug Classes

5) Atypical Antipsychotics: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs), Glutamate Modulators, Hormonal Therapies

What Is Driving The Treatment-Resistant Depression Market? High Prevalence Of Mental Disorders Driving The Market Due To Increasing Incidence Of Treatment Non-Response

The high prevalence of mental disorders is expected to propel the growth of the treatment-resistant depression market going forward. Mental disorders are a broad range of conditions that affect an individual’s cognitive, emotional, and behavioral functioning, often leading to significant distress and impairment in daily life. The high prevalence of mental disorders is driven by factors such as genetic predisposition, as inherited genetic variations can influence brain chemistry and increase susceptibility to conditions such as depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) supports mental disorder patients by encouraging the use of more personalized and advanced treatments when standard therapies don’t work, helping improve their chances of recovery and quality of life. For instance, in November 2023, according to the American Psychological Association (APA), a US-based scientific and professional organization, among adults, those aged 18 to 34 reported the highest rate of mental illnesses at 50% in 2023, while adults aged 35 to 44 experienced the largest increase in diagnoses, with 45% reporting a mental illness. Therefore, the high prevalence of mental disorders is driving the growth of the treatment-resistant depression industry.

Who Are The Major Players In The Global Treatment-Resistant Depression Market?

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, GlaxoSmithKline (GSK) plc., Hikma Pharmaceuticals plc, Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, Lykos Therapeutics, Reviva Pharmaceuticals, Celon Pharma SA, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience

What Are The Key Trends Of The Global Treatment-Resistant Depression Market? Innovative Therapies To Address Unmet Patient Needs In Treatment-Resistant Depression

Major companies operating in the treatment-resistant depression market are focusing on developing innovative therapies such as monotherapy to address unmet patient needs, improve efficacy, and reduce side effects. Monotherapy is the use of a single treatment or medication to treat a condition, rather than combining it with others. It helps to treat treatment-resistant depression by offering a single, focused treatment that may be more effective for patients who haven't responded to multiple medications. For instance, in January 2025, Johnson & Johnson Services Inc., a US-based pharmaceutical, biotechnology, and medical technology company, announced U.S. Food and Drug Administration (FDA), a US-based government regulatory body, approval for SPRAVATO (esketamine) nasal spray, a fast-acting treatment for adults with treatment-resistant depression (TRD). SPRAVATO is used alongside an oral antidepressant when patients have not responded adequately to at least two other antidepressant therapies. The drug's rapid effects address the limitations of traditional antidepressants, which often take weeks to show results. As a derivative of ketamine, esketamine works by targeting the brain's NMDA receptors, potentially improving mood within hours. The approval marked a significant advancement in the field of mental health treatment.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Treatment-Resistant Depression Market? Resilience Lab Expands Mental Health Services With Acquisition Of Options MD

In October 2024, Resilience Lab, a US-based health care company, acquired Options MD for an undisclosed amount. With this acquisition, Resilience Lab aims to strengthen its mental health service offerings by integrating Options MD’s specialized treatment platform for severe and treatment-resistant depression, thereby expanding access to personalized and evidence-based care. Options MD is a US-based telepsychiatry company treating severe and treatment-resistant depression (TRD), bipolar disorder, post-traumatic stress disorder (PTSD), and other mental health conditions.

What Is The Regional Outlook For The Global Treatment-Resistant Depression Market?

North America was the largest region in the treatment-resistant depression market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Treatment-Resistant Depression Market?

The treatment-resistant depression market consists of revenues earned by entities by providing services such as psychiatric counseling, cognitive behavioral therapy (CBT), transcranial magnetic stimulation (TMS) therapy, electroconvulsive therapy (ECT), and ketamine infusion therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The treatment-resistant depression market includes sales of products such as esketamine nasal spray, vagus nerve stimulation (VNS) devices, deep brain stimulation (DBS) systems, neuromodulation devices, glutamate receptor modulators, and digital therapeutics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Treatment-Resistant Depression Industry?

The treatment-resistant depression market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the treatment-resistant depression industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Treatment Resistant Depression Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.87 billion
Revenue Forecast In 2034	$2.44 billion
Growth Rate	CAGR of 6.8% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The treatment-resistant depression market covered in this report is segmented – 1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS), Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Psychedelics, Other Drug Classes 2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram 2) Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline 3) Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin 4) Psychedelics: Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), Other Drug Classes 5) Atypical Antipsychotics: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs), Glutamate Modulators, Hormonal Therapies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Request for Sample
Customization Scope	Explore Purchase Options
Pricing And Purchase Options

1. Executive Summary

2. Treatment-Resistant Depression Market Characteristics

3. Treatment-Resistant Depression Market Trends And Strategies

4. Treatment-Resistant Depression Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Treatment-Resistant Depression Growth Analysis And Strategic Analysis Framework

5.1. Global Treatment-Resistant Depression PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Treatment-Resistant Depression Market Growth Rate Analysis

5.4. Global Treatment-Resistant Depression Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Treatment-Resistant Depression Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Treatment-Resistant Depression Total Addressable Market (TAM)

6. Treatment-Resistant Depression Market Segmentation

6.1. Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Selective Serotonin Reuptake Inhibitors (SSRIS)

Monoamine Oxidase Inhibitors

Tricyclic Antidepressant

Psychedelics

Other Drug Classes

6.2. Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Routes Of Administration

6.3. Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.4. Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Clinics

Other End-Users

6.5. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Fluoxetine

Sertraline

Paroxetine

Citalopram

Escitalopram

6.6. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Phenelzine

Tranylcypromine

Isocarboxazid

Selegiline

6.7. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Amitriptyline

Nortriptyline

Imipramine

Clomipramine

Doxepin

6.8. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ketamine

Esketamine

Psilocybin

Lysergic Acid Diethylamide (LSD)

3,4-Methylenedioxymethamphetamine (MDMA)

Other Drug Classes

6.9. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)

Glutamate Modulators

Hormonal Therapies

7. Treatment-Resistant Depression Market Regional And Country Analysis

7.1. Global Treatment-Resistant Depression Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Treatment-Resistant Depression Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Treatment-Resistant Depression Market

8.1. Asia-Pacific Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Treatment-Resistant Depression Market

9.1. China Treatment-Resistant Depression Market Overview

9.2. China Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Treatment-Resistant Depression Market

10.1. India Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Treatment-Resistant Depression Market

11.1. Japan Treatment-Resistant Depression Market Overview

11.2. Japan Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Treatment-Resistant Depression Market

12.1. Australia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Treatment-Resistant Depression Market

13.1. Indonesia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Treatment-Resistant Depression Market

14.1. South Korea Treatment-Resistant Depression Market Overview

14.2. South Korea Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Treatment-Resistant Depression Market

15.1. Western Europe Treatment-Resistant Depression Market Overview

15.2. Western Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Treatment-Resistant Depression Market

16.1. UK Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Treatment-Resistant Depression Market

17.1. Germany Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Treatment-Resistant Depression Market

18.1. France Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Treatment-Resistant Depression Market

19.1. Italy Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Treatment-Resistant Depression Market

20.1. Spain Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Treatment-Resistant Depression Market

21.1. Eastern Europe Treatment-Resistant Depression Market Overview

21.2. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Treatment-Resistant Depression Market

22.1. Russia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Treatment-Resistant Depression Market

23.1. North America Treatment-Resistant Depression Market Overview

23.2. North America Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Treatment-Resistant Depression Market

24.1. USA Treatment-Resistant Depression Market Overview

24.2. USA Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Treatment-Resistant Depression Market

25.1. Canada Treatment-Resistant Depression Market Overview

25.2. Canada Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Treatment-Resistant Depression Market

26.1. South America Treatment-Resistant Depression Market Overview

26.2. South America Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Treatment-Resistant Depression Market

27.1. Brazil Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Treatment-Resistant Depression Market

28.1. Middle East Treatment-Resistant Depression Market Overview

28.2. Middle East Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Treatment-Resistant Depression Market

29.1. Africa Treatment-Resistant Depression Market Overview

29.2. Africa Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Treatment-Resistant Depression Market Competitive Landscape And Company Profiles

30.1. Treatment-Resistant Depression Market Competitive Landscape

30.2. Treatment-Resistant Depression Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. GlaxoSmithKline (GSK) plc. Overview, Products and Services, Strategy and Financial Analysis

31. Treatment-Resistant Depression Market Other Major And Innovative Companies

31.1. Hikma Pharmaceuticals plc

31.2. Neurocrine Biosciences Inc.

31.3. Relmada Therapeutics Inc.

31.4. Neuronetics Inc.

31.5. COMPASS Pathways

31.6. Lykos Therapeutics

31.7. Reviva Pharmaceuticals

31.8. Celon Pharma SA

31.9. BrainsWay Ltd.

31.10. Magstim Company Limited

31.11. MindMed

31.12. Alto Neuroscience

31.13. Sage Therapeutics Inc.

31.14. MindBio Therapeutics Ltd.

31.15. Reunion Neuroscience

32. Global Treatment-Resistant Depression Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Treatment-Resistant Depression Market

34. Recent Developments In The Treatment-Resistant Depression Market

35. Treatment-Resistant Depression Market High Potential Countries, Segments and Strategies

35.1 Treatment-Resistant Depression Market In 2029 - Countries Offering Most New Opportunities

35.2 Treatment-Resistant Depression Market In 2029 - Segments Offering Most New Opportunities

35.3 Treatment-Resistant Depression Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Treatment-Resistant Depression Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Treatment-Resistant Depression Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Pfizer Inc. Financial Performance

Table 81: Johnson & Johnson Services Inc. Financial Performance

Table 82: Abbott Laboratories Financial Performance

Table 83: Novartis AG Financial Performance

Table 84: GlaxoSmithKline (GSK) plc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Treatment-Resistant Depression Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Treatment-Resistant Depression Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Pfizer Inc. Financial Performance

Figure 81: Johnson & Johnson Services Inc. Financial Performance

Figure 82: Abbott Laboratories Financial Performance

Figure 83: Novartis AG Financial Performance

Figure 84: GlaxoSmithKline (GSK) plc. Financial Performance

Emerging Trends and Growth Drivers in the Pediatric Dental Market Through 2029

Competitive and Market Trend Analysis of Pharmaceutical Cold Chain Packaging Industry Through 2029

Key Market Drivers, Trends, and Forecast for the Global Pharmaceutical Warehousing Industry

2025 Analysis: Opportunities and Risks in the Evolving Precision Genomic Testing Market

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Explore the latest trends, growth insights, and forecasts in the Nutrition Analysis Software Global Market.

Explore the latest trends, growth insights, and forecasts in the Global Wearable Fitness Trackers Market.

Major Depressive Disorder Global Market Report 2025 – By Treatment (Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments), By Diagnosis (Physical Examinat...

Music Therapy Global Market Report 2025 – By Type (Receptive, Active), By Application (Traumatic, Chronic Pain, Substance Abuse Disorder, Neurodevelopment Disorder), By End-User (School, Hospital, Rehabilitation Center, ...

Behavioral Therapy Global Market Report 2025 – By Type (Cognitive Behavioral Therapy, Systematic Desensitization, Aversion Therapy, Cognitive Behavioral Play Therapy, Other Types), By Treatment Settings (Hospitals, Commu...

Bipolar Disorder Therapeutics Global Market Report 2025 – By Drug Class (Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs), By Mechanism (Selective Serotonin Reuptake Inhibitors, Serotonin-norepin...

Addictions Therapeutics Global Market Report 2025 – By Drug Type (Buprenorphine, Naltrexone, Bupropion, Disulfiram, Nicotine Replacement Products, Varenicline, Other Drugs), By Treatment Type (Opioid Addiction Treatment,...

Mental Health Apps Global Market Report 2025 – By Platform Type (iOS, Android, Other Platform Types), By Application Type (Depression and Anxiety management, Meditation Management, Stress Management, Wellness Management,...

Addictions Therapeutics Global Market Report 2025 – By Drug Type (Buprenorphine, Naltrexone, Bupropion, Disulfiram, Nicotine Replacement Products, Varenicline, Other Drugs), By Treatment Type (Opioid Addiction Treatment,...

Frequently Asked Questions

What is the definition of the Treatment-Resistant Depression market?

How will the Treatment-Resistant Depression market drivers and restraints affect the market dynamics? What forces will shape the Treatment-Resistant Depression industry going forward?

The market major growth driver - High Prevalence Of Mental Disorders Driving The Market Due To Increasing Incidence Of Treatment Non-Response. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Treatment-Resistant Depression market?

The treatment-resistant depression market size has grown strongly in recent years. It will grow from $1.76 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rising cases of treatment-resistant depression, increasing incidence of depression, increasing access to healthcare facilities, growing awareness regarding available treatment options, and high prevalence of mental disorders. The treatment-resistant depression market size is expected to see strong growth in the next few years. It will grow to " $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to an increase in chronic diseases, increasing prevalence of anxiety disorders, growing awareness of mental health, increase in government initiatives, and increase in healthcare expenditure. Major trends in the forecast period include telemedicine and digital health expansion, advancements in diagnostic and therapeutic technologies, mental health awareness and stigma reduction, adoption of personalized medicine, and use of artificial intelligence. For further insights on this market, request a sample here

How is the Treatment-Resistant Depression market segmented?

The treatment-resistant depressionmarket covered in this report is segmented –
1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS); Monoamine Oxidase Inhibitors; Tricyclic Antidepressant; Psychedelics; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users Subsegments:
1) Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine; Sertraline; Paroxetine; Citalopram; Escitalopram
2) Monoamine Oxidase Inhibitors (MAOIs): Phenelzine; Tranylcypromine; Isocarboxazid; Selegiline
3) Tricyclic Antidepressants (TCAs): Amitriptyline; Nortriptyline; Imipramine; Clomipramine; Doxepin
4) Psychedelics: Ketamine; Esketamine; Psilocybin; Lysergic Acid Diethylamide (LSD); 3,4-Methylenedioxymethamphetamine (MDMA); Other Drug Classes
5) Atypical Antipsychotics: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs); Glutamate Modulators; Hormonal Therapies For further insights on this market, request a sample here

Which region has the largest share of the Treatment-Resistant Depression market? What are the other regions covered in the report?

North America was the largest region in the treatment-resistant depression market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Treatment-Resistant Depression market?

What are the key trends in the Treatment-Resistant Depression market?

Major trends in this market include Innovative Therapies To Address Unmet Patient Needs In Treatment-Resistant Depression. For further insights on this market, request a sample here.